Tesi

Tesi is the state-owned investment company of Finland, headquartered in Helsinki and operating as a corporate venture investor with a mandate to develop domestic capital markets. The healthcare focus covers health IT and medical devices, alongside broader exposure to Finnish growth companies in other sectors. The firm does not publicly position itself around artificial intelligence as a defining thesis. Limited public information is available about specific named investment partners or a curated public portfolio at the disclosed sub-vertical level, but Tesi is widely recognized as a long-running anchor for Finnish venture and growth capital.

Tesi typically engages at Series A, Series B, and growth stages, with direct check sizes commonly described in the one to five million dollar range, supplemented by larger fund commitments where it acts as a limited partner. Geographic concentration is Finland, with selective involvement in Nordic and broader European syndicates supporting Finnish portfolio companies. The firm participates in mixed equity rounds rather than leading aggressive early-stage entries, and its capital tends to support scale-up phases where Finnish technology companies need durable institutional backing to compete internationally.

For founders, Tesi is best approached as a co-investor that values syndicate quality, governance discipline, and credible plans for sustainable growth. Companies based in Finland or with substantial Finnish operations are the natural fit, particularly in health IT, healthcare software, and medical devices where local engineering and clinical strengths align with Tesi’s mandate. Expect a process that resembles institutional growth investing rather than pure venture, with attention to financial controls, board composition, and longer holding periods. Founders should arrive with clear unit economics and a path to international expansion that justifies state-affiliated capital deployment.